Welcome to our dedicated page for Clene news (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene stock.
Clene Inc. (Nasdaq: CLNN) is a clinical-stage biopharmaceutical leader developing novel nanocrystal therapies for neurodegenerative diseases. This page provides investors and researchers with essential updates on Clene’s progress in treating ALS, multiple sclerosis, and Parkinson’s disease through its innovative Clean-Surface Nanocrystal (CSN) platform.
Find authoritative coverage of Clene’s clinical trials, including updates on lead candidate CNM-Au8®’s impact on mitochondrial health and oxidative stress biomarkers. Track regulatory developments, partnership announcements with research institutions, and analyses of trial data from Phase 2/3 studies. Our curated news collection helps stakeholders monitor Clene’s unique approach to neurodegeneration through nanotechnology.
Key updates include progress toward FDA submissions, Expanded Access Program results, and peer-reviewed research publications. Bookmark this page for real-time access to earnings reports, strategic collaborations, and scientific presentations that demonstrate Clene’s position at the forefront of neurotherapeutic innovation.
Clene Inc. (Nasdaq: CLNN) reported its first quarter 2024 financial results and operating highlights, showcasing significant data from the Phase 2 VISIONARY-MS clinical trial of CNM-Au8® demonstrating repair and remyelination. The company also received a $7.3 million NIH grant for the ALS Expanded Access Program and had $27.9 million in cash and marketable securities as of March 31, 2024. Clene continues to advance its FDA discussions in ALS and aims to file a New Drug Application in 2024.
FAQ
What is the current stock price of Clene (CLNN)?
What is the market cap of Clene (CLNN)?
